Complete response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT mutations and high tumour mutational burden

Pathological complete response (pathCR) in rectal cancer is beneficial, as up to 75% of patients do not experience regrowth of the primary tumour, but it is poorly understood. We hypothesised that the changes ...

Source: Radiation Oncology - July 13, 2021 Category: Cancer & Oncology Authors: Joanne D. Stockton, Louise Tee, Celina Whalley, Jonathan James, Mark Dilworth, Rachel Wheat, Thomas Nieto, Ian Geh, Jo ão D. Barros-Silva and Andrew D. Beggs Tags: Research Source Type: research